Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Active not recruiting 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neurofibromatosis 1 2Neurofibroma, Plexiform 2Peripheral Nervous System Diseases 1Neoplasms, Nerve Tissue 1Heredodegenerative Disorders, Nervous System 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Carboplatin 33Pemetrexed 25Cisplatin 23Paclitaxel 20Radiotherapy 16Docetaxel 16Gemcitabine 15durvalumab 14Radiosurgery 14pembrolizumab 13Nivolumab 13Erlotinib Hydrochloride 10Taxes 8atezolizumab 7Magnetic Resonance Spectroscopy 7Drug Therapy 6Cyclophosphamide 6Bevacizumab 6Platinum 5Gefitinib 5130-nm albumin-bound paclitaxel 5Etoposide 4Biopsy 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4spartalizumab 3sotorasib 3poly ICLC 3capmatinib 3Surveys and Questionnaires 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Non-Small-Cell Lung × AZD 6244 × Clear all
NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡